All In Biotech

Drug Trial Radar · NCT07737600

A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer

Phase Ib/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of MRG007 Combination Therapy in Patients With Advanced Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

316

Planned (sponsor's estimate)

Start

Aug 2026

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Lead sponsor
Lepu Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of MRG007 combination therapy in patients with advanced colorectal cancer.

Conditions

  • Advanced Colorectal Cancer

Interventions

  • MRG007Drug

    MRG007 will be administrated as specified in the protocol.

  • 5-Fluorouracil / Leucovorin CalciumDrug

    5-Fluorouracil / Leucovorin Calcium will be administrated as specified in the protocol.

  • BevacizumabDrug

    Bevacizumab will be administrated as specified in the protocol.

  • OxaliplatinDrug

    Oxaliplatin will be administrated as specified in the protocol.

  • PD-1/VEGF antibodyDrug

    PD-1/VEGF antibody will be administrated as specified in the protocol.

  • CapecitabineDrug

    Capecitabine will be administrated as specified in the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicity (DLT)Time frame: From the first dose to 30 days after the last dose
  2. Serious Adverse Events (SAEs)Time frame: From the first dose to 30 days after the last dose
  3. Adverse Event (AE)Time frame: From the first dose to 30 days after the last dose
  4. Recommended Phase 2 Dose(RP2D) and/or Maximum Tolerated Dose (MTD)Time frame: From the first dose to 30 days after the last dose
  5. Objective Response Rate (ORR)Time frame: Assessments will be performed every 6 weeks (± 7 days) following the first dose.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University cancer Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.